3.3 Impact of drugs on the prevalence of COVID-19
Drugs used by patients with ARDs
impact the infection of COVID-19(Figure p4). The regression analysis
showed that anti-rheumatic medication did not contribute to the risk of
COVID-19(Figure p5 and p6). From the
perspective of the primary drugs, the prevalence of ARD patients mainly
using GC, bDMARDs, csDMARDs, and anti-TNF therapy was
0.088(95%CI:0.065-0.110), 0.041(95%CI:0.031-0.051),
0.055(95%CI:0.043-0.067) and 0.029(95%CI:0.003-0.056),
respectively(Figure 3). Patients
mainly using GC had the highest prevalence, and those using anti-TNF
therapy had the lowest prevalence.